evipedia.ai
← Back

sh-Polypeptide-59 for Hair Regrowth

Evidence Review created on 08/24/2026 using AI4L / Opus 5

Also known as: Recombinant Human Platelet-Derived Growth Factor-B, rhPDGF-B, rhPDGF-BB, Becaplermin, SH-POLYPEPTIDE-59

Motivation

sh-Polypeptide-59 is the cosmetic labelling name for a laboratory-made copy of a human signalling protein, platelet-derived growth factor B, grown in bacteria rather than taken from any human or animal donor. It appears in a small number of premium scalp serums and shampoos, included on the reasoning that a protein the body itself uses to wake resting hair follicles might do the same when applied to the scalp.

The protein is not new. The same molecule, made the same way, has been sold as a prescription wound gel for nearly three decades, and it is one of the growth factors released by platelets in the blood-derived scalp injections that hair clinics have offered for years. What is new is the attempt to deliver it as a leave-on topical rather than through a needle.

This review examines what is known and not known about sh-Polypeptide-59 applied to the scalp for hair regrowth: how the protein behaves in follicle biology, whether it can cross intact skin, what the human evidence on related growth-factor preparations shows, what the safety record of the same protein in medical use looks like, and how the available protocols are built.

Benefits - Risks - Protocol - Conclusion

High-level material on growth-factor signalling in the hair follicle and on the peptide serums that carry sh-Polypeptide-59.

Five items are listed. Content from Rhonda Patrick, Chris Kresser and Lifespan.io was searched for but is not listed: their hair coverage concerns nutrient status, autoimmune hair loss, plant inhibitors of 5-alpha-reductase (the enzyme that produces the follicle-shrinking androgen) and follicle stem-cell research news, none of which discusses topical growth-factor peptides in substantial depth.

Grokipedia

No Grokipedia article exists for sh-Polypeptide-59.

Examine

No Examine article exists for sh-Polypeptide-59. Examine covers orally ingested supplements and does not catalogue cosmetic topical ingredients.

ConsumerLab

No ConsumerLab article exists for sh-Polypeptide-59. ConsumerLab tests ingestible supplements and does not review cosmetic scalp serums.

Systematic Reviews

Pooled evidence on growth-factor preparations for hair and on the identical recombinant protein in medical use; none of these papers tests sh-Polypeptide-59 itself.

On the trade-off, the claimed effect is represented by the first three papers, but the principal risk — the long-term safety of repeatedly applying a signal that tells cells to divide onto scalp skin — is unrepresented, because no systematic review or meta-analysis addresses it; the Tavelli review is the closest proxy, and it covers a different tissue over a shorter horizon.

Two structural biases deserve naming here, at the first citation of this literature. First, the growth-factor efficacy reviews appear predominantly in aesthetic-surgery journals and are authored by clinicians and dermatologists who themselves perform and bill for these injections; the Alali and Behrangi papers both originate from hospital dermatology and aesthetic-surgery departments, and both flag serious risk of bias in the primary studies they pool. Second, there is no institutional payer for hair regrowth — insurers and national health systems classify it as cosmetic and fund none of it — so the usual counterweight of a payer with an incentive to demand hard efficacy data is entirely absent, and the funding and publication incentives run one way: toward the sellers of the more expensive option. The same caution applies symmetrically to sources that sell competing products, including the pharmaceutical manufacturers of the established agents and the hair-clinic and ingredient-supplier blogs cited elsewhere in this review.

Mechanism of Action

sh-Polypeptide-59 is the INCI (International Nomenclature of Cosmetic Ingredients) name for a single-chain protein of up to 241 amino acids, transcribed from a synthetic copy of the human PDGFB gene and expressed in Escherichia coli. Its mature form is the B chain of platelet-derived growth factor, which assembles into the PDGF-BB dimer of roughly 25 kilodaltons.

PDGF-BB activates two receptor enzymes: PDGFRβ (platelet-derived growth factor receptor beta, the switch on connective-tissue cells) with high affinity and PDGFRα with lower affinity. In skin these sit on cells of the dermal papilla (the signalling cluster at the base of each follicle), the dermal sheath and the follicular epithelium. Engagement drives the PI3K/Akt and MAPK/ERK cascades (two general cell-survival and cell-division pathways), producing fibroblast proliferation, recruitment of pericytes that stabilise new capillaries, and matrix deposition. In mouse skin, injected PDGF-AA or PDGF-BB pushed resting follicles into anagen (the active growth phase) and raised Shh, Lef-1 and Wnt5a, the follicle-patterning genes (Tomita et al., 2006).

Pharmacologically it behaves as a protein, not a small molecule: no cytochrome P450 (the liver’s main drug-processing enzyme family) involvement, clearance by local proteolysis and receptor internalisation, a circulating half-life of minutes, negligible systemic exposure topically, and distribution confined to the treated tissue.

The competing mechanistic reading is delivery. The intact stratum corneum (the skin’s outer barrier layer) admits little above roughly 500 daltons (Bos & Meinardi, 2000), so any topical effect must arise from entry down the follicle opening, barrier disruption, or the other ingredients in the formula.

Historical Context & Evolution

Platelet-derived growth factor was isolated in the 1970s as the serum factor that makes fibroblasts divide, and its cloning in 1983 produced one of the defining results in cancer biology: the B chain proved nearly identical to the v-sis oncogene of simian sarcoma virus, the first demonstration that an oncogene could be a normal growth factor. That dual identity — repair signal and transforming protein — has shadowed every therapeutic use since.

Its original intended use was wound repair. In 1997 the US Food and Drug Administration approved becaplermin gel, recombinant human PDGF-BB, for neuropathic diabetic foot ulcers, the first recombinant growth factor licensed for wound healing; approvals for periodontal and orthopaedic bone regeneration followed. In 2008 a boxed warning was added after a claims-database analysis (Ziyadeh et al., 2011) found a fivefold higher cancer mortality among heavy users. Extending that same cohort’s follow-up by three years removed the signal, and the warning was lifted in 2018 — a sequence worth reading as evidence on both sides rather than as a refutation, since the original finding was real in its data and the null result rests on a wider exposure window.

The hair application arrived from a separate line: receptor work on hair-canal formation in the 1990s, then anagen induction by injected PDGF in mice. Cosmetic chemistry adopted it once the industry’s ingredient-naming body issued “sh-“ labelling names for synthetic human proteins, and sh-Polypeptide-59 began appearing in premium scalp serums in the mid-2020s.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: the class of evidence required — a human hair endpoint such as terminal hair density or a standardised hair count, measured with sh-Polypeptide-59 as the tested agent in more than one controlled trial — does not exist for this molecule.

Medium 🟩 🟩

No benefit reaches Medium either: there is no single controlled trial, and no consistent observational dataset, measuring a hair outcome with sh-Polypeptide-59 as the tested agent; the nearest human evidence pools multi-component growth-factor preparations in which its contribution cannot be isolated.

Low 🟩

Improved Hair Density and Shaft Caliber from Growth-Factor Preparations

Growth-factor preparations applied or injected into the scalp raise measured hair density and shaft diameter, presumably by restoring the anagen-promoting signals that shrinking follicles lose. The evidence is two meta-analyses, but the tested materials are complex mixtures rather than this protein, study-to-study variation exceeded 90%, and bias was rated high.

Magnitude: Pooled hair density rose by 14.93 hairs/cm² (95% CI 10.20–19.67; CI meaning confidence interval, the range the true value most likely occupies) and thickness by 18.67 µm in the conditioned-medium meta-analysis of Chien et al., 2024; injected concentrates reached 57.1 hairs/cm² at twelve months in Alali et al., 2026.

Improved Scalp Dermal Thickness and Quality

Beyond the follicle, growth-factor exposure thickens the scalp dermis, the tissue bed a follicle sits in. The mechanism is fibroblast proliferation and matrix deposition, which is what this protein does best. The evidence is one uncontrolled 40-patient trial with ultrasound endpoints, so it is suggestive only.

Magnitude: Dermal thickness and dermal echogenicity (ultrasound brightness, a proxy for tissue density) both increased significantly by six months in Narita et al., 2020; the study was single-arm and reports no placebo-controlled effect size, so the literature gives no comparative outcome figure.

Speculative 🟨

Induction of the Active Growth Phase

Injected PDGF-BB drove resting mouse follicles into anagen within days and raised the follicle-patterning genes. No human outcome data exist; the basis is animal work only (Tomita et al., 2006).

Maintenance of Hair-Follicle Dermal Stem Cells

Receptor deletion depletes the dermal stem cells that repopulate the dermal papilla, while PDGF-BB expands them and improves their hair-inducing capacity. The basis is mouse genetics and cell culture only (González et al., 2017).

Perifollicular Blood-Vessel Support

PDGF-BB recruits pericytes that stabilise new capillaries, and the anagen follicle depends on an expanded blood supply. The basis is vascular biology and narrative review, with no controlled human hair data (Shimizu et al., 2022).

Benefit-Modifying Factors

  • Genetic polymorphisms: Androgen receptor sensitivity, the dominant genetic driver of pattern hair loss, is unaffected by growth-factor signalling. Variants in PDGFRB have not been studied as response modifiers, so any pharmacogenetic claim on a product label is unsupported.

  • Baseline biomarker levels: Low ferritin (the iron storage protein), low 25-hydroxyvitamin D, thyroid dysfunction and zinc deficiency each independently suppress anagen. A follicle held in telogen (the resting phase) by nutrient deficiency will not respond until that deficiency is corrected.

  • Sex-based differences: Female pattern hair loss features diffuse thinning with preserved follicle openings and generally lower androgen drive, so a regenerative rather than anti-androgen mechanism has more room to work. No sex-stratified data exist for this molecule.

  • Pre-existing health conditions: Scarring alopecias destroy the follicle and its dermal papilla permanently, leaving no target. Scalp inflammation, seborrhoeic dermatitis (greasy scaling and redness) and uncontrolled diabetes each blunt regenerative signalling and are treated before response is judged.

  • Age-related considerations: Follicle dermal stem cell pools deplete with age, and the pooled regenerative-medicine data report only modest density gains overall (Behrangi et al., 2026). Adults in their sixties and beyond with long-standing bald zones have fewer viable targets remaining.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Application-Site Skin Reactions

Topical preparations of this protein cause local erythema (redness), rash and application-site irritation. The mechanism is a mix of direct stimulation of superficial skin and reaction to the gel or serum vehicle rather than to the protein alone. The evidence is human adverse-event reporting from more than one randomised trial of the identical protein, plus consistently mild, transient local reactions across regenerative scalp studies. Severity is low and reactions resolve on stopping; the trial populations were ulcer patients, not intact scalp.

Magnitude: In the pooled analysis of four randomised trials by Smiell et al., 1999, adverse events were similar in nature and incidence across becaplermin, placebo gel and no-gel groups, and only mild transient local events were reported across 724 patients in Behrangi et al., 2026; the literature reports no scalp-specific incidence figure, because no trial has applied this protein to the scalp.

Medium 🟥 🟥

Displacement of Therapies with Demonstrated Regrowth

The substantive risk for someone who can afford either option is spending 6–12 months on an unproven serum while miniaturisation (the progressive shrinking of hair follicles) continues, forgoing agents with replicated hair-count gains. The mechanism is simple opportunity cost: pattern hair loss is progressive, and follicles lost to fibrosis do not return. The evidence is the consistent trial data behind the established options, which a peptide serum must beat rather than merely coexist with.

Magnitude: The network meta-analysis of Gupta et al., 2018 ranked low-level laser therapy the superior option and found platelet-rich plasma, finasteride, minoxidil 5%, minoxidil 2% and dutasteride approximately equivalent on mean hair-count change; no head-to-head trial of a growth-factor serum against any of them has reported, so the literature gives no figure for the size of the loss.

Low 🟥

Cancer and Cancer-Mortality Signal ⚠️ Conflicted

A cancer-mortality boxed warning sat on this protein’s wound-gel form from 2008 to 2018. The concern is real: its B chain is the cellular counterpart of a viral oncogene. Human data conflict — an early analysis found excess mortality among heavy users, longer follow-up did not. Net reading: no risk demonstrated.

Magnitude: In Ziyadeh et al., 2011, the hazard ratio (the relative rate of an event between groups) for cancer incidence was 1.2 (95% CI 0.7–1.9); cancer mortality was 5.2 (95% CI 1.7–17.6) through 2003 among those with three or more dispensings, but 1.0 (95% CI 0.5–2.3) overall with follow-up extended to 2006. The dataset covers ulcer patients over a few years, not decades of daily scalp use.

Adverse Events from Microneedling-Assisted Delivery

Because the protein cannot cross intact skin, protocols pair it with microneedling or fractional laser, and the delivery method carries its own risks: pain, pinpoint bleeding, prolonged redness, pigment change and, with poor hygiene, folliculitis (infected follicles). The evidence is a systematic review of 22 low-quality studies.

Magnitude: No serious adverse events were reported across 657 microneedled subjects in English et al., 2022; minor events were not tabulated by rate, so the literature gives no incidence figure for the common reactions.

Speculative 🟨

Fibrotic and Scarring Response in Non-Wounded Scalp

PDGF-BB is the archetypal driver of fibroblast division, and pushing matrix deposition into intact skin is a different proposition from closing an ulcer. No human data exist; the concern is extrapolation from its licensed use.

Aggravation of PDGFB-Driven Cutaneous Lesions

Dermatofibrosarcoma protuberans (an uncommon skin sarcoma) arises from a COL1A1::PDGFB fusion that floods the tumour with this ligand. Whether topical exposure could feed an occult lesion is untested; the basis is tumour biology alone.

Immunogenicity to a Bacterially Expressed Protein

Repeated cutaneous exposure to a recombinant protein carrying residual Escherichia coli host-cell proteins could in principle sensitise. Becaplermin trials found no neutralising antibodies, but no scalp product has been assessed.

Risk-Modifying Factors

  • Genetic polymorphisms: A personal history of dermatofibrosarcoma protuberans, the tumour driven by a COL1A1::PDGFB fusion, marks the one point where this protein’s biology meets a known tumour driver. No common polymorphism modifies topical risk.

  • Baseline biomarker levels: No circulating marker predicts tolerance. Elevated high-sensitivity C-reactive protein (a blood marker of inflammation) or an inflamed, scaling scalp signals a compromised barrier, which raises both penetration and irritation.

  • Sex-based differences: No sex difference in local tolerance has been documented. Women more often combine scalp serums with chemical processing and heat styling, which disrupt the barrier and can amplify irritant reactions to the vehicle.

  • Pre-existing health conditions: Active scalp psoriasis, seborrhoeic dermatitis or eczema breach the barrier and raise absorption. Skin-cancer history, actinic keratoses (rough precancerous sun-damage patches) on a bald scalp, or keloid (raised overgrown scar) tendency shifts the cell-growth concerns upward.

  • Age-related considerations: Older adults with sun-damaged, thinner scalp skin carry more actinic keratoses and a higher baseline skin-cancer rate, so the untested long-term question matters more at 65 than at 35, even though no human data quantify it.

Key Interactions & Contraindications

  • Topical minoxidil (caution, additive irritation): Layering a peptide serum over minoxidil compounds propylene-glycol and alcohol irritation and can cause contact dermatitis. Protocols separate the applications by at least 12 hours — minoxidil at night, serum in the morning.

  • Topical or oral finasteride and dutasteride (no known interaction, mechanistically complementary): These block dihydrotestosterone, the androgen that miniaturises follicles, while a growth factor targets the regenerative side. No pharmacokinetic interaction is expected, since the protein is not metabolised by liver enzymes.

  • Topical tretinoin and other retinoids (caution, barrier disruption): Retinoids thin the stratum corneum, increasing both delivery and irritation. Consequence is stinging, erythema and peeling. Staggering the two by 24 hours during retinoid initiation, with reassessment after, is the usual mitigation.

  • Ketoconazole and salicylic acid shampoos (monitor, no direct interaction): Scale-dissolving and antifungal shampoos strip scalp lipids. Consequence is amplified serum sting. Thorough rinsing and a fully dry scalp before application limit it.

  • Supplements with additive scalp or bleeding effects (caution): High-dose fish oil, vitamin E, ginkgo and garlic extracts raise bleeding tendency, which matters when the serum is delivered by microneedling. Protocols pause them 5–7 days before a needling session.

  • Supplements supporting the same endpoint (monitor for attribution error): Oral saw palmetto, marine collagen, biotin and iron repletion all move hair measures independently. Adding them simultaneously makes any observed change unattributable.

  • Microneedling and fractional laser (caution, potentiating): These are the delivery methods, not incidental co-treatments. They multiply dermal exposure to the protein and to every other ingredient in the vehicle, raising both potential effect and irritation.

  • Corticosteroid scalp solutions (clobetasol, betamethasone) (monitor, opposing): Topical steroids suppress fibroblast proliferation and matrix synthesis, the exact processes this protein drives. Concurrent use plausibly blunts any benefit; protocols separate the courses in time rather than combining them.

Populations who should avoid sh-Polypeptide-59:

  • Anyone with a current or prior scalp malignancy, including basal cell carcinoma, squamous cell carcinoma, melanoma or dermatofibrosarcoma protuberans, absent dermatological clearance
  • Anyone with active, untreated actinic keratoses on the scalp (more than isolated lesions, or any thickened, tender or bleeding lesion)
  • Anyone with an active scarring alopecia — lichen planopilaris, frontal fibrosing alopecia or folliculitis decalvans — in the inflammatory phase
  • Anyone with open scalp wounds, ulceration or an active scalp infection
  • Anyone with a known keloid or hypertrophic scarring tendency who intends to use microneedled delivery
  • Pregnant or breastfeeding individuals, on absence of data rather than evidence of harm

Risk Mitigation Strategies

  • Dermatoscopic scalp check before starting: A magnified dermatologist examination excludes actinic keratoses, occult skin cancer and scarring alopecia, the three conditions that turn an untested cell-growth exposure from theoretical into imprudent.

  • Patch test on a 2 cm area for 7 days: Applying to one small scalp or forearm site first surfaces vehicle-driven contact dermatitis before the whole scalp is exposed, which is the single most likely adverse event.

  • Application to intact, unbroken skin only: Withholding the serum whenever the scalp is cut, scratched, sunburnt or actively inflamed limits dermal absorption of both protein and vehicle, mitigating irritation and the scarring and cell-growth concerns.

  • Separation of microneedling and serum by 24 hours: Needling first, then applying the following day rather than immediately, reduces deep dermal deposition of preservatives and fragrance, which mitigates persistent inflammatory lumps and lasting pigment change.

  • A trial capped at one hair cycle with photographs: A fixed 6-month standardised-photography endpoint mitigates the opportunity-cost risk by forcing an explicit decision rather than open-ended spending on an unproven agent.

  • An established agent run in parallel: Maintaining minoxidil, finasteride or low-level laser therapy alongside the serum prevents the loss of ground that occurs when a proven treatment is dropped to test an unproven one.

  • Daily scalp sun protection: A hat or mineral sunscreen on thinning or bald areas reduces ultraviolet-driven mutation load, the plausible co-factor for any cell-growth concern about repeated growth-factor exposure.

Therapeutic Protocol

  • Standard practitioner approach: Aesthetic and hair-restoration clinics apply multi-growth-factor serums immediately after fractional or microneedling passes, typically monthly for 4–6 sessions, mirroring the conditioned-medium protocols of Fukuoka and Suga’s Tokyo group.

  • Competing approach — leave-on cosmetic: Consumer products such as premium peptide serums direct once- or twice-daily application to a dry scalp with no device. Neither approach has outperformed the other in a head-to-head trial.

  • Competing approach — injection: Intradermal delivery of growth-factor concentrates bypasses the barrier entirely and carries most of the published human data, at the cost of clinic visits, needles and roughly ten times the price.

  • Best time of day: Evening application on a dry scalp is usual, allowing 6–8 hours of undisturbed contact before washing. No circadian data exist for this protein; timing is driven by hair-washing routine, not chronobiology.

  • Half-life: As a protein, its scalp residence is governed by proteolysis and receptor internalisation, not systemic clearance; the circulating half-life is minutes. Daily reapplication is therefore the norm, not weekly dosing.

  • Single versus split dosing: Split dosing has no pharmacological rationale here. A single evening application of 1–2 mL is standard; splitting merely halves each dose without extending receptor occupancy.

  • Genetic polymorphisms influencing protocol: No pharmacogenetic testing informs dosing. Androgen receptor CAG repeat length and 5-alpha-reductase variants influence response to anti-androgens, not to growth factors, so they guide the companion therapy instead.

  • Sex-based differences: Women more often start from diffuse thinning with intact follicle openings and no anti-androgen backbone; men more often combine with finasteride. No dose difference is described in any protocol.

  • Age-related considerations: Adults past 60 with long-standing bald zones have depleted follicle stem-cell pools and less to gain; protocols in that group typically pair the serum with microneedling rather than using it alone.

  • Baseline biomarker levels: Ferritin, vitamin D, thyroid function and zinc are corrected before starting. Beginning a serum on top of an uncorrected deficiency produces an uninterpretable result and wastes a hair cycle.

  • Pre-existing health conditions: Seborrhoeic dermatitis and scalp psoriasis are treated first. An inflamed scalp both alters absorption and confounds any density change attributed to the serum.

Discontinuation & Cycling

  • Lifelong or short-term: No maintenance data exist. Since pattern hair loss is progressive and this protein does nothing to the androgen driver, any gain would require continuous use, as with minoxidil.

  • Withdrawal effects: None documented. There is no receptor downregulation syndrome and no rebound shedding reported for topical recombinant PDGF-BB, unlike the shed seen when minoxidil is stopped abruptly.

  • Tapering: Not applicable. A topical protein with a minutes-long half-life and no systemic accumulation can be stopped outright; no taper protocol has been described or is mechanistically warranted.

  • Cycling: No evidence supports cycling for efficacy. Loss of response with repeated exposure has not been demonstrated for this protein in skin, so scheduled breaks have no rationale beyond reducing exposure and cost.

  • Assessing after stopping: Any gain would be expected to regress over one to two hair cycles, roughly 6–18 months. A standardised photograph at the point of stopping is the only way to judge that later.

Sourcing and Quality

  • The INCI name on the label: The panel must read “sh-Polypeptide-59”. Marketing terms such as “growth factor complex” or “PDGF peptide” without the INCI listing indicate the ingredient may be absent or present at token levels.

  • Disclosed concentration or activity: Almost no consumer product states parts-per-million or bioactivity units. Absence of a stated concentration means potency cannot be assessed, and undisclosed formulas remain unquantified.

  • Cold-chain and opaque, airless packaging: Recombinant proteins degrade with heat, light and oxidation. Jars and clear bottles are poor choices; refrigerated shipping and single-direction pumps preserve activity better.

  • Third-party testing: Cosmetic peptides fall outside supplement testing programmes. The available check is a certificate of analysis showing protein identity and purity by HPLC (high-performance liquid chromatography, a separation assay) and ELISA (enzyme-linked immunosorbent assay, an antibody-based quantification).

  • Named raw-material suppliers: The sh-peptide raw materials in most finished products originate from a small number of South Korean biotechnology houses, notably Caregen and BIO-FD&C. Finished-product examples include Blueprint’s peptide serum and Labo Crescina shampoos.

  • Compounding pharmacies: Not a route here. Compounders supply minoxidil and finasteride formulations, but recombinant growth factors are not compounded for cosmetic scalp use in most jurisdictions.

Practical Considerations

  • Time to effect: Nothing meaningful can be judged before one hair cycle. Regenerative scalp studies report measurable density changes at 3–6 months and continuing gains to 12 (Alali et al., 2026); assessment before 16 weeks is uninformative.

  • Common pitfall — expecting it to replace anti-androgen therapy: A growth factor does not touch dihydrotestosterone. Used alone in active pattern hair loss it addresses the regenerative half of the problem while the driver continues unchecked.

  • Common pitfall — applying to wet hair or washing too soon: Dilution and early rinsing negate contact time. Protocols specify a dry scalp parted in sections and at least 6 hours before washing.

  • Common pitfall — changing several variables at once: Starting the serum, a supplement and microneedling in the same month makes attribution impossible and often means paying indefinitely for the component that did nothing.

  • Regulatory status: In the US and EU it is a cosmetic ingredient with no efficacy review; the identical protein is a prescription drug (becaplermin) for diabetic foot ulcers. China’s regulator prohibits human epidermal growth factor in cosmetics and scrutinises growth factors as a class.

  • Cost and accessibility: Serums containing it sit at roughly $100–180 for 50 mL, or $1,200–2,000 a year, against about $100–150 a year for generic minoxidil. Clinic-delivered growth-factor sessions cost considerably more.

Interaction with Foundational Habits

  • Sleep: No direct interaction — the protein is not systemically absorbed and has no central activity. The indirect link runs the other way: chronic short sleep raises cortisol and is associated with telogen effluvium (sudden diffuse shedding), so poor sleep can mask any topical gain. Evening application fits an existing wind-down routine.

  • Nutrition: Indirect but decisive. A growth-factor signal cannot build a hair shaft without substrate: adequate protein (1.2–1.6 g/kg), iron sufficient for ferritin above 70 ng/mL, zinc, biotin and vitamin D. Correcting deficiency is the higher-yield move; crash dieting or aggressive caloric restriction pushes follicles into telogen and will override any serum.

  • Exercise: Essentially none, in either direction. There is no hypertrophy-blunting concern, since exposure is cutaneous and local. The only practical point is timing: sweat and post-workout washing strip a freshly applied serum, so protocols place application after training rather than before, and keep sauna use outside the hours around it.

  • Stress management: Indirect and potentially significant. Sustained stress shortens anagen through corticotropin-releasing hormone (the body’s stress-signal hormone) acting on the follicle, working against the anagen-promoting signal the serum is meant to supply. Meditation, breathing practice and sleep regularity address the driver; the serum does not.

Monitoring Protocol & Defining Success

Before starting, two baselines are established. The first is laboratory: a panel that rules out the reversible drivers of hair loss, drawn fasting and in the morning, because an uncorrected deficiency suppresses regrowth and makes any result uninterpretable. The second is photographic: standardised photographs from four fixed angles under identical lighting, plus a dermatoscopic image of a marked 1 cm² area at the vertex, the only way to detect the small density changes at stake.

Ongoing monitoring repeats the laboratory panel at 3 months if any value was abnormal, otherwise at 6–12 months. Photography repeats at 4 and 6 months, then every 6 months, with weekly scalp inspection for irritation through month one. Success at 6 months means visible density gain on matched photographs or a measurable rise in the marked area, not a subjective impression of thicker hair.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Ferritin 70–100 ng/mL Iron stores gate anagen entry Ferritin is the iron storage protein. Conventional labs flag only below 15–30 ng/mL, far below the hair threshold. Acute-phase reactant — best paired with high-sensitivity C-reactive protein to avoid a falsely reassuring value.
25-hydroxyvitamin D 40–60 ng/mL Receptor is required for follicle cycling Conventional sufficiency starts at 30 ng/mL. Non-fasting; stable year-round in supplemented individuals, otherwise seasonal.
TSH 0.5–2.0 mIU/L Thyroid dysfunction causes diffuse shedding TSH is thyroid-stimulating hormone. Conventional range extends to 4.5 mIU/L. Morning draw; best paired with free T4 (free thyroxine) and thyroid peroxidase antibodies if elevated.
Plasma zinc 90–120 µg/dL Deficiency produces brittle hair and shedding Conventional lower limit is 60–70 µg/dL. Fasting, morning draw; supplements withheld for 24 hours and trace-element-free tubes required.
High-sensitivity CRP <1.0 mg/L Flags scalp or systemic inflammation confounding response CRP is C-reactive protein, a general inflammation marker. Conventional cut-off is 3.0 mg/L. Deferred if unwell — any recent infection invalidates it.
Free testosterone and DHT No established target for topical growth-factor use; track against the individual’s own baseline Establishes whether an androgen driver is present and untreated DHT is dihydrotestosterone, the androgen that miniaturises follicles. Morning draw. Relevant to choosing a companion anti-androgen, not to dosing the serum.
Marked-area hair density ≥10% gain over baseline at 6 months The actual endpoint the serum claims Dermatoscopic count of a tattooed or precisely mapped 1 cm² vertex area, same magnification and lighting each time.

Qualitative markers worth tracking alongside the numbers:

  • Shedding volume — hairs counted in the shower drain or on the pillow weekly, at a fixed day and time
  • Scalp comfort — itch, burning, tightness or flaking after application
  • Hair shaft feel — coarseness and body of regrowing hairs at the hairline and part
  • Styling behaviour — whether the part line narrows and the hair holds volume through the day
  • Confidence in appearance under bright overhead light, the condition that exposes density loss most

Emerging Research

  • Peptide serum against the established comparator: NCT07536100 at the Institute of Dermatology, Thailand, is recruiting 80 participants to compare a peptide growth-factor hair serum with topical 2% minoxidil in pattern hair loss, with change in hair density as the primary endpoint. This is the head-to-head design the category currently lacks.

  • Energy-assisted delivery: NCT07079657 at Universitätsklinikum Hamburg-Eppendorf is recruiting 30 participants to test thulium laser with and without a growth-factor serum, isolating whether the serum adds anything once the barrier is already breached — the question that decides the topical route.

  • Delivery method versus growth-factor content: NCT06218394 enrolled 135 women to compare microneedling, autologous concentrated growth factor and 5% minoxidil, with total area hair count as the endpoint. A null result for the growth-factor arm would weaken the whole category.

  • The competing direction: NCT07317544, an Absci phase 1/2 study of ABS-201 in 227 adults, pursues a systemically dosed biologic rather than a topical growth factor. If it succeeds, cosmetic peptide serums lose their claim to being the sophisticated option.

  • Solving the penetration problem: Shin et al., 2025 conjugated low-molecular-weight protamine to a platelet-derived growth factor chain and reported improved cell permeability and 5-alpha-reductase inhibition in dermal papilla cells — the kind of carrier chemistry that would have to work for an unmodified protein serum to be plausible.

  • Downstream mediators as a better target: Jeong et al., 2020 showed the growth factor acts on human hair shafts partly through epiregulin, raising the possibility that a smaller downstream molecule delivers the effect more efficiently than the parent protein.

  • The safety question that remains open: the matched-cohort evidence of Ziyadeh et al., 2011 covers ulcer patients over a few years. No study has followed daily scalp application over a decade, and none is registered — an unresolved gap that could weaken the case.

Conclusion

sh-Polypeptide-59 is a laboratory-made copy of a human repair protein that the body uses to wake resting hair follicles and to build the tissue around them. Its biology is genuinely relevant to hair: in animals the protein restarts the growth phase, and it keeps alive the stem cells that rebuild the base of the follicle. As a medicine, injected or placed into wounds, the same protein has a long and reassuring safety record.

What is missing is the step in between. No trial has tested this ingredient on a human scalp. The supporting human evidence comes from mixed growth-factor preparations delivered by needle, and it requires a generous benefit of the doubt: the studies are small, inconsistent, and mostly conducted and published by the clinicians and companies who sell the treatments, in a field where no insurer pays and therefore no one with money at stake demands proof. The protein is also far too large to cross unbroken skin, so a leave-on serum faces a physical obstacle its marketing rarely mentions.

The known harms are minor and local. The real cost is the hair cycle spent finding out, at ten times the price of options with replicated results. For someone willing to run it alongside an established treatment and photograph the outcome at six months, the downside is money and patience rather than safety.

Top - Benefits - Risks - Protocol